Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention

Experimental Biology and Medicine

Volumn 229, Issue 7, 2004, Pages 567-585

  Mo, Huanbiao ^a   Elson, Charles E ^b  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; Apoptosis; Cell cycle arrest; Isoprenoid; Lovastatin; Perillyl alcohol; tocotrienol

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BETA IONONE; FARNESOL; FARNESYL DERIVATIVE; FARNESYL DIPHOSPHATE; FARNESYLAMINE; GAMMA TOCOTRIENOL; GERANIOL; GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; L 778123; LAMIN; LIMONENE; LONAFARNIB; MEVALONIC ACID; MEVINOLIN; PERILLYL ALCOHOL; PHENYLACETATE SODIUM; POTASSIUM; PRAVASTATIN; SIMVASTATIN; SODIUM PHENYLBUTYRATE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; AMINO ACID SYNTHESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; ERUCTATION; FATIGUE; FEEDBACK SYSTEM; FEVER; GASTROINTESTINAL TOXICITY; GENE CONTROL; GENE SEQUENCE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOKALEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MITOSIS INHIBITION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; SEIZURE; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOMNOLENCE; STOMACH ADENOCARCINOMA; TASTE DISORDER; TRANSCRIPTION REGULATION; ULCER; VOMITING;

EID: 3042736080     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422900701     Document Type: Short Survey

References (223)

1. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 221:294-311, 1999.
2. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21:505-517, 1980.
3. Schmidt RA, Schneider CJ, Glomset JA. Evidence for posttranslational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J Biol Chem 259:10175-10180, 1984.
4. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 264:20422-20429, 1989.
5. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269, 1996.
6. Hutchison CJ, Bridger JM, Cox LS, Kill IR. Weaving a pattern from disparate threads: lamin function in nuclear assembly and DNA replication. J Cell Sci 107:3259-3269, 1994.
7. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 205:1681-1687, 1994.
8. Ghosh PM, Mott GE, Ghosh-Choudhury N, Radnik RA, Stapleton ML, Ghidoni JJ, Kreisberg JI. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim Biophys Acta 1359:13-24, 1997.
9. Hawk MA, Cesen KT, Siglin JC, Stoner GD, Ruch RJ. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett 109:217-222, 1996.
10. Sumi S, Beauchamp RD, Townsend CM, Pour PM, Ishizuka J, Thompson JC. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9:657-661, 1994.
11. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199:1209-1215, 1994.
12. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 273:10618-10623, 1998.
13. Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 54:891-895, 1994.
14. Harrison LE, Wojciechowicz DC, Brennan MF, Paty PB. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery 124:541-550, 1998.
15. Finzer P, Stohr M, Seibert N, Rosl F. Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number. J Cancer Res Clin Oncol 129:107-113, 2003.
16. DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, Gore SD. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia 13:1243-1253, 1999.
17. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 58:1636-1649, 2001.
18. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491, 1996.
19. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21:579-583, 1998.
20. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81-83, 2001.
21. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 40:659-662, 2001.
22. Lovastatin Study Groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 153:1079-1087, 1993.
23. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363-2368, 2000.
24. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84:886-891, 2001.
25. Jeppesen U, Gaist D, Smith T, Sindrup SH. Statins and peripheral neuropathy. Eur J Clin Pharmacol 54:835-838, 1999.
26. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 58:1333-1337, 2002.
27. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519, 2002.
28. Carducci MA, Bowling MK, Eisenberger MA, Sinibaldi V, Simons JW, Chen TL, Noe D, Grochow LB, Donehower RC. Phenylbutyrate (PB) for refractory solid tumors: a phase I clinical and pharmacologic evaluation. Proc Am Soc Clin Oncol 15:A1542, 1996.
29. Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35:368-373, 1995.
30. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, Myers CE. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54:1690-1694, 1994.
31. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938, 1995.
32. Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 74:137-145, 1999.
33. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17:984-990, 1999.
34. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941, 2000.
35. Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JH. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726-2735, 2002.
36. Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 12:193-197, 2001.
37. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21:2492-2499, 2003.
38. Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21:1760-1766, 2003.
39. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 97:3361-3369, 2001.
40. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000.
41. Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 38:2272-2278, 2002.
42. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19:1167-1175, 2001.
43. Sharma S, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 13:1067-1071, 2002.
44. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 38:1685-1700, 2002.
45. Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin Cancer Res 9:4761-4771, 2003.
46. Caponigro F, Casale M, Bryce J. Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs 12:943-954, 2003.
47. Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S, Spriggs D. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 7:3894-3903, 2001.
48. Hahn SM, Bernhard EJ, Regine W, Mohiuddin M, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, DeLaney TF, Kiel KD, Morrison B, Deutsch P, Muschel RJ, McKenna WG. A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002.
49. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47:1405-1415, 1994.
50. Crowell PL, Lin S, Vedejs E, Gould MN. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth. Cancer Chemother Pharmacol 31:205-212, 1992.
51. Crowell PL, Chang RR, Ren ZB, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266:17679-17685, 1991.
52. Chow HH, Salazar D, Hakim IA. Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content. Cancer Epidemiol Biomarkers Prev 11:1472-1476, 2002.
53. Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC. Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 42:111-117, 1998.
54. Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 51:493-498, 2003.
55. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6:3071-3080, 2000.
56. Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I study of perillyl alcohol in patients with refractory malignancies. Cancer Biol Ther 1:130-135, 2002.
57. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4:1159-1164, 1998.
58. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6:390-396, 2000.
59. Liu G, Oettel K, Bailey H, Van Ummersen L, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 21:367-372, 2003.
60. Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol 85:464-468, 2002.
61. Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 32:125-128, 2002.
62. Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 52:361-366, 2003.
63. Elson CE. Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease. J Nutr 125:1666s-1672s, 1995.
64. Tatman D, Mo H. Volatile isoprenoid constituents of fruits, vegetables and herbs cumulatively suppress the proliferation of murine B16 melanoma and human HL-60 leukemia cells. Cancer Lett 175:129-139, 2002.
65. Stayrook KR, McKinzie JH, Burke YD, Burke YA, Crowell PL. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 18:1655-1658, 1997.
66. Ariazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, Gould MN. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59:1917-1928, 1999.
67. Sahin MB, Perman SM, Jenkins G, Clark SS. Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 13:1581-1591, 1999.
68. Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr 129:804-813, 1999.
69. Adany I, Yazlovitskaya EM, Haug JS, Voziyan PA, Melnykovych G. Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture. Cancer Lett 79:175-179, 1994.
70. Rioja A, Pizzey AR, Marson CM, Thomas NS. Preferential induction of apoptosis of leukaemic cells by farnesol. FEBS Lett 467:291-295, 2000.
71. Smalley KS, Eisen TG. Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 98:514-522, 2002.
72. Yazlovitskaya EM, Melnykovych G. Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. Cancer Lett 88:179-183, 1995.
73. Ura H, Obara T, Shudo R, Itoh A, Tanno S, Fujii T, Nishino N, Kohgo Y. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Mol Carcinog 21:93-99, 1998.
74. Clark SS, Zhong L, Filiault D, Perman S, Ren Z, Gould M, Yang X. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion. Clin Cancer Res 9:4494-4504, 2003.
75. McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224:292-301, 2000.
76. Guthrie N, Gapor A, Chambers AF, Carroll KK. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and - positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 127:544S-548S, 1997.
77. Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 30:1139-1143, 1995.
78. Crowell PL, Elson CE. Isoprenoids, health and disease. In: Wildman REC, Ed. Handbook of Nutraceuticals and Functional Foods. CRC Series in Modern Nutrition. Boca Raton, FL: CRC Press, pp31-53, 2001.
79. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 266:12216-12222, 1991.
80. Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 32:151-156, 1997.
81. Voziyan PA, Goldner CM, Melnykovych G. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem J 295:757-762, 1993.
82. Shoff SM, Grummer M, Yatvin MB, Elson CE. Concentration-dependent increase of murine P388 and B16 population doubling time by the acyclic monoterpene geraniol. Cancer Res 51:37-42, 1991.
83. Bardon S, Picard K, Martel P. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 32:1-7, 1998.
84. Elegbede JA, Flores R, Wang RC. Perillyl alcohol and perillaldehyde induced cell cycle arrest and cell death in BroTo and A549 cells cultured in vitro. Life Sci 73:2831-2840, 2003.
85. Ferri N, Arnaboldi L, Orlandi A, Yokoyama K, Gree R, Granata A, Hachem A, Paoletti R, Gelb MH, Corsini A. Effect of S(-) perillic acid on protein prenylation and arterial smooth muscle cell proliferation. Biochem Pharmacol 62:1637-1645, 2001.
86. Shi W, Gould MN. Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 23:131-142, 2002.
87. Voziyan PA, Haug JS, Melnykovych G. Mechanism of farnesol cytotoxicity: further evidence for the role of PKC-dependent signal transduction in farnesol-induced apoptotic cell death. Biochem Biophys Res Commun 212:479-486, 1995.
88. Haug JS, Goldner CM, Yazlovitskaya EM, Voziyan PA, Melnykovych G. Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: effect of phosphatidylcholine. Biochim Biophys Acta 1223:133-140, 1994.
89. Miquel K, Pradines A, Favre G. Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 225:869-876, 1996.
90. Miquel K, Pradines A, Terce F, Selmi S, Favre G. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem 273:26179-26186, 1998.
91. Perez-Sala D, Gilbert BA, Rando RR, Canada FJ. Analogs of farnesylcysteine induce apoptosis in HL-60 cells. FEBS Lett 426:319-324, 1998.
92. Mo H, Tatman D, Jung M, Elson CE. Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. Cancer Lett 157:145-153, 2000.
93. McAnally JA, Jung M, Mo H. Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. Cancer Lett 202:181-192, 2003.
94. Jirtle RL, Haag JD, Ariazi EA, Gould MN. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53:3849-3852, 1993.
95. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55:979-983, 1995.
96. Reddy BS, Wang CX, Samaha H, Lubet R, Steele VE, Kelloff GJ, Rao CV. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 57:420-425, 1997.
97. Kothapalli R, Lui EM, Guthrie N, Chambers AF, Carroll KK. Effects of long-chain fatty amines on the growth of ras-transformed NIH 3T3 cells. Biochem Pharmacol 47:1909-1916, 1994.
98. Mizukami Y, Ura H, Obara T, Habiro A, Izawa T, Osanai M, Yanagawa N, Tanno S, Kohgo Y. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. Biochem Biophys Res Commun 288:198-204, 2001.
99. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38:1267-1272, 1995.
100. Hamada M, Nishio K, Doe M, Usuki Y, Tanaka T. Farnesylpyridinium, an analog of isoprenoid farnesol, induces apoptosis but suppresses apoptotic body formation in human promyelocytic leukemia cells. FEBS Lett 514:250-254, 2002.
101. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127:668-674, 1997.
102. Komiyama K, Iizuka K, Yamaoka M, Watanabe H, Tsuchiya N, Umezawa I. Studies on the biological activity of tocotrienols. Chem Pharm Bull (Tokyo) 37:1369-1371, 1989.
103. Ishihara M, Takayama F, Toguchi M, Nakano K, Yasumoto E, Nakayachi T, Satoh K, Sakagami H. Cytotoxic activity of polyprenylalcohols and vitamin K2 derivatives. Anticancer Res 20:4307-4313, 2000.
104. Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K, Toyama K. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia 11:779-787, 1997.
105. Bentinger M, Grunler J, Peterson E, Swiezewska E, Dallner G. Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. Arch Biochem Biophys 353:191-198, 1998.
106. Westfall D, Aboushadi N, Shackelford JE, Krisans SK. Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. Biochem Biophys Res Commun 230:562-568, 1997.
107. Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 91:169-175, 1995.
108. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161:17-26, 2002.
109. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 59:245-254, 2000.
110. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 41:13698-13704, 2002.
111. Holstein SA, Hohl RJ. Monoterpene regulation of Ras and Ras-related protein expression. J Lipid Res 44:1209-1215, 2003.
112. Crowell PL, Elson CE, Bailey HH, Elegbede A, Haag JD, Gould MN. Human metabolism of the experimental cancer therapeutic agent d-limonene. Cancer Chemother Pharmacol 35:31-37, 1994.
113. Ren Z, Elson CE, Gould MN. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 54:113-120, 1997.
114. Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, Crowell DN. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett 110:49-55, 1996.
115. Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL. Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res 18:823-828, 1998.
116. Lluria-Prevatt M, Morreale J, Gregus J, Alberts DS, Kaper F, Giaccia A, Powell MB. Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 11:573-579, 2002.
117. Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, Jarman M. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 57:801-809, 1999.
118. Graham SM, Cox AD, Drivas G, Rush MG, D'Eustachio P, Der CJ. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol Cell Biol 14:4108-4115, 1994.
119. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. Dislodgment and accelerated degradation of Ras. Biochemistry 37:1306-1314, 1998.
120. Egozi Y, Weisz B, Gana-Weisz M, Ben-Baruch G, Kloog Y. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 80:911-918, 1999.
121. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8:555-565, 2002.
122. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22:1061-1067, 2001.
123. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and posttranslational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 277:10678-10682, 2002.
124. Broitman SA, Wilkinson JT, Cerda S, Branch SK. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv Exp Med Biol 401:111-130, 1996.
125. Burke YD, Ayoubi AS, Wemer SR, McFarland BC, Heilman DK, Ruggeri BA, Crowell PL. Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res 22:3127-3134, 2002.
126. Bardon S, Foussard V, Foumel S, Loubat A. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett 181:187-194, 2002.
127. Satomi Y, Miyamoto S, Gould MN. Induction of AP-1 activity by perillyl alcohol in breast cancer cells. Carcinogenesis 20:1957-1961, 1999.
128. Giri RK, Parija T, Das BR. d-limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-jun and c-myc. Oncol Rep 6:1123-1127, 1999.
129. Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 22:1727-1731, 2001.
130. Park WH, Lee YY, Kim ES, Seol JG, Jung CW, Lee CC, Kim BK. Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res 19:3133-3140, 1999.
131. Garcia-Roman N, Alvarez AM, Toro MJ, Montes A, Lorenzo MJ. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci 17:329-341, 2001.
132. Ukomadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 278:43586-43594, 2003.
133. Ukomadu C, Dutta A. Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 278:4840-4846, 2003.
134. Oda H, Kasiske BL, O'Donnell MP, Keane WF. Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Kidney Int Suppl 71:S202-205, 1999.
135. Blanco-Colio LM, Justo P, Daehn I, Lorz C, Ortiz A, Egido J. Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. Kidney Int 64:181-191, 2003.
136. Ghosh PM, Moyer ML, Mott GE, Kreisberg JI. Effect of cyclin E overexpression on lovastatin-induced G1 arrest and RhoA inactivation in NIH3T3 cells. J Cell Biochem 74:532-543, 1999.
137. Martinez-Gonzalez J, Vinals M, Vidal F, Llorente-Cortes V, Badimon L. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135:213-223, 1997.
138. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57:604-609, 1997.
139. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibition of Ras famesylation by lovastatin leads to down-regulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20:2761-2771, 2000.
140. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16:6917-6925, 1996.
141. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 56:133-142, 2002.
142. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 272:27224-27229, 1997.
143. Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275:31001-31008, 2000.
144. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA
145. Peffley DM, Gayen AK. Plant-derived monoterpenes suppress hamster kidney cell 3-hydroxy-3-methylglutaryl coenzyme a reductase synthesis at the posttranscriptional level. J Nutr 133:38-44, 2003.
146. Ariazi EA, Gould MN. Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display. J Biol Chem 271:29286-29294, 1996.
147. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10:1492-1497, 1990.
148. Daniel CW, Robinson SD. Regulation of mammary growth and function by TGF-beta. Mol Reprod Dev 32:145-151, 1992.
149. Ravitz MJ, Wenner CE. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res 71:165-207, 1997.
150. Moustakas A, Kardassis D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci U S A 95:6733-6738, 1998.
151. Wright MM, Henneberry AL, Lagace TA, Ridgway ND, McMaster CR. Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis. J Biol Chem 276:25254-25261, 2001.
152. Terce F, Brun H, Vance DE. Requirement of phosphatidylcholine for normal progression through the cell cycle in C3H/10T1/2 fibroblasts. J Lipid Res 35:2130-2142, 1994.
153. Anthony ML, Zhao M, Brindle KM. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem 274:19686-19692, 1999.
154. Lagace TA, Miller JR, Ridgway ND. Caspase processing and nuclear export of CTP:phosphocholine cytidylyltransferase alpha during farnesol-induced apoptosis. Mol Cell Biol 22:4851-4862, 2002.
155. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343:425-430, 1990.
156. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 275:32379-32382, 2000.
157. Vallett SM, Sanchez HB, Rosenfeld JM, Osborne TF. A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3- methylglutaryl coenzyme A reductase gene. J Biol Chem 271:12247-12253, 1996.
158. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131, 2002.
159. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99:846-854, 1997.
160. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340, 1997.
161. Meigs TE, Simoni RD. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch Biochem Biophys 345:1-9, 1997.
162. Correll CC, Edwards PA. Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J Biol Chem 269:633-638, 1994.
163. Meigs TE, Roseman DS, Simoni RD. Regulation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 271:7916-7922, 1996.
164. Bradfute DL, Simoni RD. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J Biol Chem 269:6645-6650, 1994.
165. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by posttranscriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 268:11230-11238, 1993.
166. Pearce BC, Parker RA, Deason ME, Dischino DD, Gillespie E, Qureshi AA, Volk K, Wright JJ. Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. J Med Chem 37:526-541, 1994.
167. Peffley DM, Gayen AK. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Arch Biochem Biophys 337:251-260, 1997.
168. Clegg RJ, Middleton B, Bell GD, White DA. The mechanism of cyclic monoterpene inhibition of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the rat. J Biol Chem 257:2294-2299, 1982.
169. Case GL, He L, Mo H, Elson CE. Induction of geranyl pyrophosphate pyrophosphatase activity by cholesterol-suppressive isoprenoids. Lipids 30:357-359, 1995.
170. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 84:2689-2698, 1994.
171. Yachnin S, Mannickarottu V. Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells. Blood 63:690-693, 1984.
172. Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55:640-645, 1993.
173. Hentosh P, Yuh SH, Elson CE, Peffley DM. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 32:154-166, 2001.
174. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet 3 Spec No: 1487-1495, 1994.
175. Rossiello MR, Rao PM, Rajalakshmi S, Sarma DS. Similar patterns of hypomethylation in the beta-hydroxy-beta-methylglutaryl coenzyme A reductase gene in hepatic nodules induced by different carcinogens. Mol Carcinog 10:237-245, 1994.
176. Coni P, Pang J, Pichiri-Coni G, Hsu S, Rao PM, Rajalakshmi S, Sarma DS. Hypomethylation of beta-hydroxy-beta-methyl-glutaryl coenzyme A reductase gene and its expression during hepatocarcinogenesis in the rat. Carcinogenesis 13:497-499, 1992.
177. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838-845, 1997.
178. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated fatty acids down-regulate SREBP isoforms 1a and 1c by two mechanisms in HEK-293 cells. J Biol Chem 276:4365-4372, 2001.
179. Yang YA, Morin PJ, Han WF, Chen T, Bomman DM, Gabrielson EW, Pizer ES. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132-137, 2003.
180. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W, Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19:5173-5181, 2000.
181. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80-90, 2002.
182. Li JN, Mahmoud MA, Han WF, Ripple M, Pizer ES. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res 261:159-165, 2000.
183. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98:1575-1584, 1996.
184. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 100:2115-2124, 1997.
185. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77:53-62, 1994.
186. George R, Goldfarb S. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid. Cancer Res 40:4717-4721, 1980.
187. Yu SG, Abuirmeileh NM, Qureshi AA, Elson CE. Dietary β-ionone suppresses hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. J Agric Food Chem 42:1493-1496, 1994.
188. Hua X, Nohturfft A, Goldstein JL, Brown MS. Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 87:415-426, 1996.
189. Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry 42:4384-4391, 2003.
190. Cerda SR, Wilkinson J IV, Thorgeirsdottir S, Broitman SA. R-(+)-perillyl alcohol-induced cell cycle changes, altered actin cytoskeleton, and decreased ras and p34cdc2 expression in colonic adenocarcinoma SW480 cells. J Nutr Biochem 10:19-30, 1999.
191. Elson CE, Yu SG. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables. J Nutr 124:607-614, 1994.
192. Schwenke DC. Does lack of tocopherols and tocotrienols put women at increased risk of breast cancer? J Nutr Biochem 13:2-20, 2002.
193. Sinensky M, Logel J. Defective macromolecule biosynthesis and cell-cycle progression in a mammalian cell starved for mevalonate. Proc Natl Acad Sci U S A 82:3257-3261, 1985.
194. Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, Yuo A, Ohyashiki K. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15:1111-1117, 2001.
195. Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 42:1-11, 1999.
196. McCarty MF. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses 56:12-16, 2001.
197. Larsson O. Cell cycle-specific growth inhibition of human breast cancer cells induced by metabolic inhibitors. Glycobiology 3:475-479, 1993.
198. Larsson O. Effects of isoprenoids on growth of normal human mammary epithelial cells and breast cancer cells in vitro. Anticancer Res 14:123-128, 1994.
199. Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J, Carlberg M, Larsson O. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 7:625-633, 1997.
200. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17:2393-2402, 1998.
201. Reuveni H, Klein S, Levitzki A. The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur J Biochem 270:2759-2772, 2003.
202. Clark SS, Perman SM, Sahin MB, Jenkins GJ, Elegbede JA. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16:213-222, 2002.
203. Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 33:26-32, 1999.
204. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 40:167-178, 2000.
205. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93:1308-1318, 1999.
206. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:838-847, 1999.
207. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223-2229, 1999.
208. Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026, 2003.
209. Flach J, Antoni I, Villemin P, Bentzen CL, Niesor EJ. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Commun 270:240-246, 2000.
210. Odysseos AD, Vraka P, Bouralexis S, Frindlay DM, Papas A, Evdokiou A. Gamma-tocotrienol triggers caspase-mediated induction of apoptosis in androgen-responsive, but not androgen unresponsive prostate cancer cells in vitro. Free Radic Res 36:116-117, 2002.
211. Shah S, Gapor A, Sylvester PW. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer 45:236-246, 2003.
212. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76-83, 1998.
213. Ishikura H, Mochizuki T, Izumi Y, Usui T, Sawada H, Uchino H. Differentiation of mouse leukemic M1 cells induced by polyprenoids. Leuk Res 8:843-852, 1984.
214. Hanley K, Komuves LG, Ng DC, Schoonjans K, He SS, Lau P, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 275:11484-11491, 2000.
215. Chao JT, Gapor A, Theriault A. Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo) 48:332-337, 2002.
216. Iqbal J, Minhajuddin M, Beg ZH. Suppression of 7,12-dimethylbenz[alpha] anthracene-induced carcinogenesis and hypercholesterolaemia in rats by tocotrienol-rich fraction isolated from rice bran oil. Eur J Cancer Prev 12:447-453, 2003.
217. Cerda SR, Wilkinson JT, Branch SK, Broitman SA. Enhancement of sterol synthesis by the monoterpene perillyl alcohol is unaffected by competitive 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. Lipids 34:605-615, 1999.
218. Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270:17508-17512, 1995.
219. Eummer JT, Gibbs BS, Zahn TJ, Sebolt-Leopold JS, Gibbs RA. Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors. Bioorg Med Chem 7:241-250, 1999.
220. McGuire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem Biophys Res Commun 204:399-406, 1994.
221. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52:1016-1027, 1997.
222. Graham TE, Pfeiffer JR, Lee RJ, Kusewitt DF, Martinez AM, Foutz T, Wilson BS, Oliver JM. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling. J Immunol 161:6733-6744, 1998.
223. Caresecchi S, Schneider Y, Ceraline J, Duranton B, Gosse F, Seiler N, Raul F. Geraniol, a component of plant essential oils, inhibits growth and polyamine biosynthesis in human colon cancer cells. J Pharmacol Exp Ther 298:197-200, 2001.